EA200702435A1 - Иммуномодулирующие гетероциклические соединения - Google Patents
Иммуномодулирующие гетероциклические соединенияInfo
- Publication number
- EA200702435A1 EA200702435A1 EA200702435A EA200702435A EA200702435A1 EA 200702435 A1 EA200702435 A1 EA 200702435A1 EA 200702435 A EA200702435 A EA 200702435A EA 200702435 A EA200702435 A EA 200702435A EA 200702435 A1 EA200702435 A1 EA 200702435A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- heterocyclic compounds
- immunomodulating
- immunomodulating heterocyclic
- solvate
- hydrate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Surgery (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Соединения формулы (I) являются ингибиторами CD80 и применимы в иммуномодулирующей терапии, где Rи R, независимо, обозначают Н; F; Cl; Br; -NO, -CN; C-Салкил, необязательно замещённый F или Cl; или C-Салкокси, необязательно замещённый F; Rобозначает карбоксильную кислотную группу (-СООН) или её эфир, или -C(=O)NRR, -NRC(=O)R, -NRC(=O)OR, -NHC(=O)NRRили -NHC(=S)NRR, где Rобозначает Н или радикал формулы -(Alk)-Q, где m обозначает 0 или 1, Alk обозначает необязательно замещённый двухвалентный линейный или разветвлённый C-Cалкиленовый, или C-Салкениленовый, или C-Салкиниленовый радикал, или двухвалентный С-Cкарбоциклический радикал, любой из этих радикалов может содержать одну или более -О-, -S- или - N(R)- связей, где Rобозначает Н или C-Cалкил, С-Cалкенил, С-Cалкинил, или С-Сциклоалкил, и Q обозначает Н; -NRR, где Rи R, независимо, обозначают Н; C-Cалкил; С-Cалкенил; С-Cалкинил; С-Сциклоалкил; сложноэфирную группу; необязательно замещённую карбоциклическую или гетероциклическую группу; или Rи Rвместе с атомом азота, с которым они связаны, образуют цикл, который, необязательно, является замещённым; и Rобозначает Н или C-Салкил, или Rи Rвместе с атомом или атомами, с которым(и) они связаны, образуют необязательно замещённый моноциклический гетероцикл, содержащий 5, 6 или 7 атомов в цикле; и Х обозначает связь или двухвалентный радикал формулы -(Z)-(Alk)- или -(Alk)-(Z)-, где Z обозначает -О-, -S- или -NH-, Alk имеет значение по определению для R, а n обозначает 0 или 1.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0305876A GB0305876D0 (en) | 2003-03-14 | 2003-03-14 | Immuno inhibitory heterocyclic compounds |
| GB0319429A GB0319429D0 (en) | 2003-08-19 | 2003-08-19 | Immuno Inhibitory Heterocyclic compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA200702435A1 true EA200702435A1 (ru) | 2008-06-30 |
| EA014080B1 EA014080B1 (ru) | 2010-08-30 |
Family
ID=32992598
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA200501370A EA009680B1 (ru) | 2003-03-14 | 2004-03-10 | Иммуномодулирующие гетероциклические соединения |
| EA200702435A EA014080B1 (ru) | 2003-03-14 | 2004-03-10 | Иммуномодулирующие гетероциклические соединения |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA200501370A EA009680B1 (ru) | 2003-03-14 | 2004-03-10 | Иммуномодулирующие гетероциклические соединения |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US7276505B2 (ru) |
| EP (2) | EP2284172A1 (ru) |
| JP (1) | JP4892338B2 (ru) |
| KR (1) | KR101133959B1 (ru) |
| AT (1) | ATE489388T1 (ru) |
| BR (1) | BRPI0408365B8 (ru) |
| CA (1) | CA2519063C (ru) |
| DE (1) | DE602004030225D1 (ru) |
| DK (1) | DK1603917T3 (ru) |
| EA (2) | EA009680B1 (ru) |
| EC (1) | ECSP056104A (ru) |
| HK (1) | HK1090921A1 (ru) |
| IL (1) | IL170389A (ru) |
| MX (1) | MXPA05009667A (ru) |
| NO (1) | NO332136B1 (ru) |
| NZ (1) | NZ541973A (ru) |
| PL (2) | PL1603917T3 (ru) |
| PT (1) | PT1603917E (ru) |
| SI (1) | SI1603917T1 (ru) |
| WO (1) | WO2004081011A1 (ru) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101133959B1 (ko) * | 2003-03-14 | 2012-04-09 | 메디진 아게 | 면역조절 헤테로고리 화합물 |
| GB0325644D0 (en) * | 2003-11-04 | 2003-12-10 | Avidex Ltd | Immuno ihibitory pyrazolone compounds |
| GB0411770D0 (en) * | 2004-05-26 | 2004-06-30 | Avidex Ltd | Immuno inhibitory heterocyclic compouds |
| ATE411318T1 (de) * | 2004-08-09 | 2008-10-15 | Medigene Ltd | Immunmodulierende oxopyrazolocinnoline als cd80- inhibitoren |
| WO2007017289A2 (en) * | 2005-08-10 | 2007-02-15 | Bayer Schering Pharma Aktiengesellschaft | Acyltryptophanols for fertility control |
| GB0603522D0 (en) | 2006-02-22 | 2006-04-05 | Avidex Ltd | Kinase inhibition |
| MX2008011791A (es) | 2006-03-15 | 2008-09-25 | Wyeth Corp | Azaciclilaminas-n-sustituidas como antagonistas de histamina-3. |
| AU2007254232A1 (en) | 2006-05-19 | 2007-11-29 | Wyeth | N-benzoyl-and N-benzylpyrrolidin-3-ylamines as histamine-3 antagonists |
| WO2008004610A1 (fr) * | 2006-07-05 | 2008-01-10 | The University Of Tokyo | Méthode de traitement de maladie génétique provoquée par une mutation non sens |
| PE20081152A1 (es) * | 2006-10-06 | 2008-08-10 | Wyeth Corp | Azaciclilaminas n-sustituidas como antagonistas de histamina-3 |
| US7803825B2 (en) | 2007-07-16 | 2010-09-28 | Wyeth Llc | Aminoalkylazole derivatives as histamine-3 antagonists |
| EP2020404A1 (en) * | 2007-08-01 | 2009-02-04 | Bayer Schering Pharma Aktiengesellschaft | Cyanomethyl substituted N-Acyl Tryptamines |
| JP5362729B2 (ja) | 2007-10-04 | 2013-12-11 | エフ．ホフマン−ラ ロシュ アーゲー | シクロプロピルアリールアミド誘導体及びその使用 |
| GB201021104D0 (en) | 2010-12-13 | 2011-01-26 | Univ Leuven Kath | Novel compounds for the treatment of neurodegenerative diseases |
| EP2676666A1 (en) | 2012-06-20 | 2013-12-25 | Eidgenössische Technische Hochschule Zürich (ETH) | Compounds for use in diagnosis or therapy of vulnerable atherosclerotic plaques |
| EP2883883A1 (en) | 2013-12-16 | 2015-06-17 | Cardio3 Biosciences S.A. | Therapeutic targets and agents useful in treating ischemia reperfusion injury |
| EP3193609A4 (en) * | 2014-09-10 | 2018-02-28 | Epizyme, Inc. | Substituted pyrrolidine carboxamide compounds |
| US11046683B2 (en) | 2016-12-15 | 2021-06-29 | Ono Pharmaceutical Co., Ltd. | Activator of TREK (TWIK RElated K+ channels) channels |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB629412A (en) | 1946-12-24 | 1949-09-20 | Geigy Ag J R | Manufacture of metallisable monoazo dyestuffs of the pyrazolone series |
| US3576637A (en) | 1967-04-20 | 1971-04-27 | Konishiroku Photo Ind | Lith-type of emulsion containing pyrozolone |
| JPS61161285A (ja) * | 1984-12-28 | 1986-07-21 | ルセル−ユクラフ | ピラゾロ〔４，３−ｃ〕シンノリン−３−オンの誘導体、それらの塩類、これらの製造法、薬剤としての使用、これらを含有する組成物及び中間体生成物 |
| US4591589A (en) * | 1985-01-16 | 1986-05-27 | Roussel Uclaf | 2-aryl pyrazolo[4,3-c]cinnolin-3-ones |
| DE3626221A1 (de) | 1986-08-02 | 1988-02-04 | Agfa Gevaert Ag | Farbfotografisches aufzeichnungsmaterial zur herstellung farbiger aufsichtsbilder |
| DE3789754T2 (de) | 1986-11-20 | 1994-12-15 | Mitsubishi Chem Ind | Die Bildung von Lipid-peroxiden hemmende Zusammenstzung und dafür geeignete Verbindungen. |
| DE3903993A1 (de) | 1989-02-10 | 1990-08-16 | Basf Ag | Diarylsubstituierte heterocyclische verbindungen, ihre herstellung und arzneimittel daraus |
| AR006520A1 (es) | 1996-03-20 | 1999-09-08 | Astra Pharma Prod | Derivados de 2-arilpirazolisoquinolina y cinolinona y procedimiento para su preparacion. |
| GB9713707D0 (en) | 1997-06-27 | 1997-09-03 | Merck Sharp & Dohme | Therapeutic agents |
| SE0102404D0 (sv) * | 2001-07-04 | 2001-07-04 | Active Biotech Ab | Novel immunomodulating compounds |
| EP1411052B1 (en) | 2001-07-05 | 2011-10-05 | Takeda Pharmaceutical Company Limited | Benzo-fused 5-membered hetrocycle compounds,process for preparation of the same, and use thereof |
| US7566711B2 (en) * | 2001-10-12 | 2009-07-28 | Choongwae Pharma Corporation | Reverse-turn mimetics and method relating thereto |
| NZ540081A (en) | 2002-11-22 | 2008-03-28 | Active Biotech Ab | Pyrazoloquinolines with immunomodulating activity |
| ATE425164T1 (de) | 2002-12-16 | 2009-03-15 | Active Biotech Ab | Tetrazyklische immunmodulierende verbindungen |
| KR101133959B1 (ko) | 2003-03-14 | 2012-04-09 | 메디진 아게 | 면역조절 헤테로고리 화합물 |
| GB0325644D0 (en) | 2003-11-04 | 2003-12-10 | Avidex Ltd | Immuno ihibitory pyrazolone compounds |
| GB0411770D0 (en) | 2004-05-26 | 2004-06-30 | Avidex Ltd | Immuno inhibitory heterocyclic compouds |
| ATE411318T1 (de) | 2004-08-09 | 2008-10-15 | Medigene Ltd | Immunmodulierende oxopyrazolocinnoline als cd80- inhibitoren |
| US20060221590A1 (en) * | 2005-03-31 | 2006-10-05 | Edoardo Campini | System and method for Advanced Mezzanine Card connection |
| GB0603522D0 (en) | 2006-02-22 | 2006-04-05 | Avidex Ltd | Kinase inhibition |
-
2004
- 2004-03-10 KR KR1020057017070A patent/KR101133959B1/ko active IP Right Grant
- 2004-03-10 SI SI200431606T patent/SI1603917T1/sl unknown
- 2004-03-10 PT PT04719006T patent/PT1603917E/pt unknown
- 2004-03-10 DE DE602004030225T patent/DE602004030225D1/de not_active Expired - Lifetime
- 2004-03-10 EP EP10014524A patent/EP2284172A1/en not_active Withdrawn
- 2004-03-10 BR BRPI0408365A patent/BRPI0408365B8/pt active IP Right Grant
- 2004-03-10 US US10/547,448 patent/US7276505B2/en not_active Expired - Lifetime
- 2004-03-10 EP EP04719006A patent/EP1603917B1/en not_active Expired - Lifetime
- 2004-03-10 PL PL04719006T patent/PL1603917T3/pl unknown
- 2004-03-10 PL PL383655A patent/PL383655A1/pl unknown
- 2004-03-10 CA CA2519063A patent/CA2519063C/en not_active Expired - Lifetime
- 2004-03-10 NZ NZ541973A patent/NZ541973A/en not_active IP Right Cessation
- 2004-03-10 EA EA200501370A patent/EA009680B1/ru not_active IP Right Cessation
- 2004-03-10 DK DK04719006.1T patent/DK1603917T3/da active
- 2004-03-10 AT AT04719006T patent/ATE489388T1/de active
- 2004-03-10 EA EA200702435A patent/EA014080B1/ru not_active IP Right Cessation
- 2004-03-10 JP JP2006505937A patent/JP4892338B2/ja not_active Expired - Lifetime
- 2004-03-10 MX MXPA05009667A patent/MXPA05009667A/es active IP Right Grant
- 2004-03-10 WO PCT/GB2004/001008 patent/WO2004081011A1/en active Application Filing
-
2005
- 2005-08-18 IL IL170389A patent/IL170389A/en active IP Right Grant
- 2005-10-13 NO NO20054710A patent/NO332136B1/no unknown
- 2005-10-14 EC EC2005006104A patent/ECSP056104A/es unknown
-
2006
- 2006-10-19 HK HK06111573A patent/HK1090921A1/xx not_active IP Right Cessation
-
2007
- 2007-08-28 US US11/845,837 patent/US7598247B2/en not_active Expired - Lifetime
-
2009
- 2009-08-24 US US12/545,902 patent/US8309552B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20054710L (no) | Immunmodulerende heterosykliske forbindelser | |
| NL300927I9 (nl) | Tivozanib of een zout, solvaat of hydraat ervan, in het bijzonder het hydrochloride-monohydraat | |
| ATE377420T1 (de) | Phenylalkansäure- und phenyloxyalkansäure- derivate als hppar aktivatore | |
| HRP20070430T3 (en) | (3-oxo-3,4-dihydro-quinoxalin-2-yl-amino)-benzamide derivatives and related compounds as glycogen phosphorylase inhibitors for the treatment of diabetes and obesity | |
| GB2398781B (en) | Kinase inhibitors | |
| IL165264A0 (en) | Protein kinase inhibitors | |
| SI1585739T1 (sl) | Substituirani arilciklopropilacetamidi kot aktivatorji glukokinaze | |
| NO20061157L (no) | 4-pyramidonderivater og deres anvendelse som peptidylpeptidmeinbibitorer | |
| EA200801381A1 (ru) | Производные пиримидина | |
| AU2003229953A8 (en) | Phthalazinone derivatives | |
| NO20054669L (no) | Substituerte kinobenzoxazinanaloger | |
| DE60319080D1 (de) | Phenyloxyalkansäure-derivate als hppar aktivatore | |
| MXPA05011276A (es) | Derivado heterociclico de cinco miembros. | |
| GB0215392D0 (en) | Chemical compounds | |
| HK1086835A1 (en) | N-[({'4-substituted piperazine-1-y}sulfonylmethyl)alkyl]-n-hxdroxyformamide compounds as metallopro teinase inhibitors | |
| DE602004031878D1 (de) | Immunhemmende pyrazolon-verbindungen | |
| TW200518748A (en) | Chemical compounds | |
| WO2004103305A3 (en) | Spiropyrazole compound | |
| DOP2002000354A (es) | Compuestos farmaceuticamente activos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KG MD TJ TM |
|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): KZ RU |